Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothBrightest Minds in the CDMO industry - From early Development to Commercial Manufacturing

            Contact the Supplier

            Lead Product(s): Opicapone

            Therapeutic Area: Neurology Product Name: Ongentys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bial

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 01, 2020

            Details:

            The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levodopa,Carbidopa,Entacapone

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: STADA Arzneimittel

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 02, 2020

            Details:

            By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.